ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00109161
Recruitment Status : Completed
First Posted : April 25, 2005
Last Update Posted : August 5, 2008
Sponsor:
Information provided by:
Facet Biotech